Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer

International Journal of Radiation Oncology Biology Physics

Volumn 54, Issue 2, 2002, Pages 403-408

  Kim, Jun Sang ^a   Kim, Jae Sung ^a   Cho, Moon June ^a   Song, Kyu Sang ^a   Yoon, Wan Hee ^a,b  

^a Chungnam National University   (South Korea)

^b Chungnam National University College of Medicine   (South Korea)

Author keywords

Capecitabine; Preoperative chemoradiation; Rectal cancer

Indexed keywords

CHEMICAL ACTIVATION; CHEMOTHERAPY; TUMORS;

CHEMORADIATION;

RADIATION;

CAPECITABINE; FOLINIC ACID;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; INTESTINE OBSTRUCTION; MALE; NAUSEA; NEUROGENIC BLADDER; PELVIS ABSCESS; POSTOPERATIVE COMPLICATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RADIATION DERMATITIS; RECTOVAGINAL FISTULA; RECTUM CARCINOMA; STOMATITIS; SURGICAL TECHNIQUE; THROMBOCYTOPENIA; TREATMENT OUTCOME; WOUND HEALING IMPAIRMENT;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; RECTAL NEOPLASMS;

EID: 0036804343     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)02856-0     Document Type: Article

References (29)

1. Janjan N.A., Khoo V.S., Abbruzzese J., et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer The M.D. Anderson Cancer Center experience . Int J Radiat Oncol Biol Phys. 44:1999;1027-1038.
2. Minsky B.D., Cohen A.M., Enker W.E., et al. Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. Int J Radiat Oncol Biol Phys. 37:1997;289-295.
3. Chen E.T., Mohiuddin M., Brodovsky H., et al. Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. Int J Radiat Oncol Biol Phys. 30:1994;169-175.
4. Marks G., Mohiuddin M., Masoni L. The reality of radical sphincter preservation surgery for cancer of the distal 3 cm of rectum following high-dose radiation. Int J Radiat Oncol Biol Phys. 27:1993;779-783.
5. Valentini V., Coco C., Cellini N., et al. Preoperative chemoradiation for extraperitoneal T3 rectal cancer Acute toxicity, tumor response, and sphincter preservation . Int J Radiat Oncol Biol Phys. 40:1998;1067-1075.
6. Wagman R.W., Minsky B.D., Cohen A.M., et al. Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis Long term follow-up . Int J Radiat Oncol Biol Phys. 42:1998;51-57.
7. Kim J., Kim J., Jang J., et al. The treatment results of preoperative concurrent chemoradiation in locally advanced rectal cancer. J Korean Cancer Assoc. 32:2000;933-942.
8. Meta-analysis Group In Cancer . Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 16:1998;301-308.
9. O'Connell M.J., Martenson J.A., Wieand H.S., et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 331:1994;502-507.
10. Meta-analysis Group In Cancer . Toxicity of fluorouracil in patients with advanced colorectal cancer Effect of administration and prognostic factors . J Clin Oncol. 16:1998;3537-3541.
11. Grem J.L. Systemic treatment options in advanced colorectal cancer Perspectives on combination 5-fluorouracil plus leucovorin . Semin Oncol. 24:(Suppl. 18):1997;8-18.
12. Torre A., Ramos S., Valcarcel F.J., et al. Phase II study of radiochemotherapy with UFT, and low dose oral leucovorin in patients with unresectable rectal cancer. Int J Radiat Oncol Biol Phys. 45:1999;629-634.
13. Seong J., Cho J.H., Kim N.K., et al. Preoperative chemoradiotherapy with oral doxifluridine plus low dose oral leucovorin in unresectable primary rectal cancer. Int J Radiat Oncol Biol Phys. 50:2001;435-439.
14. Hoff P.M., Ansari R., Batist G., et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer Results of a randomized phase III study . J Clin Oncol. 19:2001;2282-2292.
15. Calvo F.A., Gómez-Espí M., Díaz-González J.A., et al. Pathologic downstaging of T3-4Nx rectal cancer after chemoradiation 5-fluorouracil vs. Tegafur . Int J Radiat Oncol Biol Phys. 51:2001;1264-1270.
16. Liu G., Franssen E., Fitch M., et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 15:1997;110-115.
17. Miwa M., Ura M., Nishida M., et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 34:1998;1274-1281.
18. Ishikawa T., Utoh M., Sawada N., et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol. 55:1998;1091-1097.
19. Schüller J., Cassidy J., Dumont E., et al. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol. 45:2000;291-297.
20. Sawada N., Ishikawa T., Sekiguchi F., et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 5:1999;2948-2953.
21. Twelves C., Boyer M., Findlay M., et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer. 37:2001;597-604.
22. Trotti A., Byhardt R., Stetz J., et al. Common toxicity criteria Version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy . Int J Radiat Oncol Biol Phys. 47:2000;13-47.
23. Mandard A.M., Dalibard F., Mandard J.C., et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer. 73:1994;2680-2686.
24. Rougier P., Paillot B., LaPlanche A., et al. 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer. Eur J Cancer. 33:1997;1789-1793.
25. Reese T., Tanner J., Frings S., et al. Capecitabine combined with simultaneous radiotherapy in rectal cancer A phase-I-study . (Abstr.) Int J Radiat Oncol Biol Phys. 48:(Suppl. 1):2000;120-121.
26. Francois Y., Nemoz C.J., Baulieux J., et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer The Lyon R90-01 randomized trial . J Clin Oncol. 17:1999;2396-2402.
27. Thrall M.M., Wood P., King V., et al. Investigation of the comparative toxicity of 5-FU bolus versus 5-FU continuous infusion circadian chemotherapy with concurrent radiation therapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 46:2000;873-881.
28. Chiara S., Nobile M.T., Barzacchi C., et al. Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. Eur J Cancer. 33:1997;967-969.
29. Berg D. Managing the side effects of chemotherapy for colorectal cancer. Semin Oncol. 25:(Suppl. 11):1998;53-59.